The Cognitive Model of Negative Symptoms in Schizophrenia: A Hierarchical Component Model With PLS-SEM

Ebrahimi, Ali; Poursharifi, Hamid; Dolatshahi, Behrooz; Rezaee, Omid; Hassanabadi, Hamidreza; Naeem, Farooq

doi:10.3389/fpsyt.2021.707291

Cited by 10 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Negative symptoms correlated positively with disability, whereas medication adherence and cognitive functions correlated negatively with disability. This is in line with findings in literature where disability is associated with negative symptoms and cognitive symptoms[ 14 , 15 ] and medication adherence improved disability. [ 16 ] Similarly, negative symptoms had negative correlation with QOL, whereas medication adherence and cognitive functions had significant positive correlation with QOL.…”

Section: Discussionsupporting

confidence: 92%

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy

Nandakumar

Ganesh

Deb

et al. 2023

Indian Journal of Psychiatry

View full text Add to dashboard Cite

Objectives: To assess disability and quality of life (QOL) in treatment resistant schizophrenia (TRS) on long term clozapine therapy and assess their correlation with positive, negative and cognitive symptoms. Methodology: Disability and QOL in forty patients with TRS (as per modified Kane’s criteria) were assessed using World Health Organization Disability Assessment Schedule 2.0 and World Health Organization Quality of Life–BREF. Scale for assessment of positive symptoms, scale for assessment of negative symptoms and Addenbrooke’s cognitive examination-III were used to assess positive, negative and cognitive symptoms. Medication adherence rating scale assessed medication adherence. Results: Disability and QOL correlated significantly with medication adherence, negative and cognitive symptoms but not with positive symptoms. Subgroup analysis revealed significant difference between medication adherence (good vs poor) and cognitive (impairment vs non-impairment) groups. Conclusion: Negative and cognitive symptoms, and medication adherence correlated with disability and QOL.

show abstract

Section: Discussionsupporting

confidence: 92%

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy

Nandakumar

Ganesh

Deb

et al. 2023

Indian Journal of Psychiatry

View full text Add to dashboard Cite

show abstract

“…Both are believed to contribute to the secondary activation of negative symptoms such as poor rapport ( 83 ) and comorbid disorders like mood and anxiety disorders ( 84 ) resulting in an increased chronification risk ( 85 ). Relevant contributing psychological processes in the development of negative symptoms thereby seem to be a demoralization due to patients’ low expectancies for pleasure or success ( 64 , 86 ), internalized stigma ( 87 ), a lack of participation and activities ( 88 ), and maladaptive coping responses such as social anhedonia and substance abuse to deal with aversive internal and external experiences ( 89 ).…”

Section: Resultsmentioning

confidence: 99%

Developing a mechanism-based therapy for acute psychiatric inpatients with psychotic symptoms: an Intervention Mapping approach

Gussmann,

Lucae,

Falkai

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundTreatment guidelines for psychosis recommend offering psychotherapy already in the acute illness phase. However, there is a lack of available interventions adapted to the specific needs and key change mechanisms of inpatients experiencing severe symptoms and crisis. In this article we outline the scientific development process of a needs-oriented and mechanism-based group intervention for acute psychiatric inpatients with psychosis (MEBASp).MethodsTo guide our intervention design, we used Intervention Mapping (IM), a six-step framework for developing evidence-based health interventions that consisted of an extensive literature review, an in-depth problem definition and needs analysis, the modeling of change mechanisms and outcomes and the production of an intervention prototype.ResultsOur low-threshold modularized group intervention consists of nine stand-alone sessions (two per week) within three modules and targets different aspects of metacognitive and social change mechanisms. Module I and II aim to reduce acute symptoms by fostering cognitive insight, Module III focuses on reducing distress via cognitive defusion. Therapy contents are adapted from existing metacognitive treatments such as the Metacognitive Training and presented in a destigmatizing, simply understandable and experience-oriented way.ConclusionMEBASp is currently evaluated in a single-arm feasibility trial. Using a systematic and rigorous development methodology and providing a detailed description of the development steps demonstrated to be invaluable in improving the intervention’s scientific foundation, validity, and replicability for similar research.

show abstract

“…Consistent with the observation related to negative symptom domains, word production showed higher correlations (especially total words written). These findings may not be surprising given that negative symptoms (including those pertaining to speech production, such as alogia and aprosody) are known to be associated with neurocognitive deficits (including those pertaining to verbal performance, such as verbal working memory) (Ebrahimi et al, 2021;Huang et al, 2016;Voruganti et al, 1997).…”

Section: Discussionmentioning

confidence: 98%

Lexical Diversity and Other Linguistic Measures in Schizophrenia

Compton¹,

Covington

et al. 2023

J Nerv Ment Dis

View full text Add to dashboard Cite

Straightforward linguistic measures may be indicators of reduced language production and lexical diversity among individuals with schizophrenia with negative symptoms and neurocognitive impairments. We compared 98 patients with schizophrenia to 101 unaffected controls on six language variables (e.g., number of relationships between objects, use of complex transitions in the narrative structure), number of words produced, and lexical diversity computed as the moving average type-token ratio from both speaking and writing tasks. Patients differed from controls on nearly all of the linguistic measures; number of words produced had the strongest effect, with an average Cohen's d of 0.68; values pertaining to lexical diversity were 0.50 and 0.32, respectively, for the speaking tasks and the writing tasks. Most measures were correlated with alogia and other domains of negative symptoms (including avolition-apathy and anhedonia-asociality), as well as with diverse neurocognitive domains, especially those pertaining to working memory, verbal learning, and verbal category fluency. Further work is needed to understand longitudinal changes in these linguistic variables, as well as their utility as measures of alogia.

show abstract

The Cognitive Model of Negative Symptoms in Schizophrenia: A Hierarchical Component Model With PLS-SEM

Cited by 10 publications

References 41 publications

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy

Developing a mechanism-based therapy for acute psychiatric inpatients with psychotic symptoms: an Intervention Mapping approach

Lexical Diversity and Other Linguistic Measures in Schizophrenia

Contact Info

Product

Resources

About